Morgan Stanley’s PROSENSA HLDGS N V ORD SHS (NLD) RNA Stock Holding History

Morgan Stanley’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-30,740	Closed	-$576K	–	6898
2014 Q4	$576K	Sell	30,740 -983	-3%	-$14K	﹤0.01%	4568
2014 Q3	$268K	Sell	31,723 -4,109	-11%	-$38.9K	﹤0.01%	4981
2014 Q2	$452K	Buy	35,832 +13,695	+62%	+$111K	﹤0.01%	4659
2014 Q1	$125K	Buy	22,137 +17,343	+362%	+$108K	﹤0.01%	5349
2013 Q4	$22K	Sell	4,794 -42,955	-90%	-$196K	﹤0.01%	5845
2013 Q3	$316K	Buy	+47,749	New	+$1.12M	﹤0.01%	4632

Morgan Stanley's RNA Position: Q1 2015 in Review

Morgan Stanley sold out of PROSENSA HLDGS N V ORD SHS (NLD) (RNA) in Q1 2015, closing a stake of 30,740 shares — an estimated $576K sold.

Morgan Stanley first reported a position in RNA in Q3 2013 and held it in 6 quarters. The position peaked at $576K in Q4 2014. 0 funds tracked by Wall St. Rank hold RNA as of Q1 2015.

Morgan Stanley reported no remaining PROSENSA HLDGS N V ORD SHS (NLD) position as of Q1 2015 after selling out during the quarter.
Morgan Stanley sold 30,740 PROSENSA HLDGS N V ORD SHS (NLD) shares in Q1 2015, an estimated $576K.
Morgan Stanley first reported a position in PROSENSA HLDGS N V ORD SHS (NLD) in Q3 2013 and held it in 6 quarters.
Morgan Stanley's PROSENSA HLDGS N V ORD SHS (NLD) position peaked at $576K in Q4 2014.
0 funds tracked by Wall St. Rank held PROSENSA HLDGS N V ORD SHS (NLD) as of Q1 2015.

Based on Morgan Stanley's 13F filing for Q1 2015, filed 14 May 2015.